EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update - PubMed (original) (raw)
Review
. 2011 Jun;59(6):997-1008.
doi: 10.1016/j.eururo.2011.03.017. Epub 2011 Mar 22.
Affiliations
- PMID: 21458150
- DOI: 10.1016/j.eururo.2011.03.017
Review
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
Marko Babjuk et al. Eur Urol. 2011 Jun.
Abstract
Context and objective: To present the 2011 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC).
Evidence acquisition: Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence (LE) and grade of recommendation (GR) were assigned.
Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. In papillary tumours, the risks of both recurrence and progression may be estimated for individual patients using the scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups-separately for recurrence and progression-is pivotal to recommending adjuvant treatment. For patients with a low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is recommended. Patients with an intermediate or high risk of recurrence and an intermediate risk of progression should receive one immediate instillation of chemotherapy followed by a minimum of 1 yr of bacillus Calmette-Guérin (BCG) intravesical immunotherapy or further instillations of chemotherapy. Papillary tumours with a high risk of progression and CIS should receive intravesical BCG for 1 yr. Cystectomy may be offered to the highest risk patients, and it is at least recommended in BCG failure patients. The long version of the guidelines is available from the EAU Web site (www.uroweb.org).
Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
- EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology. Babjuk M, et al. Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12. Eur Urol. 2013. PMID: 23827737 Review. - EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. Babjuk M, et al. Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17. Eur Urol. 2017. PMID: 27324428 - European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V, Sylvester RJ. Babjuk M, et al. Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10. Eur Urol. 2022. PMID: 34511303 Review. - European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V. Babjuk M, et al. Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20. Eur Urol. 2019. PMID: 31443960 Review. - [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M; Asociación Europea de Urología. Babjuk M, et al. Actas Urol Esp. 2012 Jul-Aug;36(7):389-402. doi: 10.1016/j.acuro.2011.12.001. Epub 2012 Mar 2. Actas Urol Esp. 2012. PMID: 22386115 Spanish.
Cited by
- Comparative study on the efficacy of low-dose and full-dose BCG bladder perfusion therapy.
Chen C, Fan G, Li P, Yang E, Jing S, Shi Y, Gong Y, Zhang L, Wang Z. Chen C, et al. Clin Transl Oncol. 2024 Sep 26. doi: 10.1007/s12094-024-03729-5. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39325262 Review. - Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer.
Chen C, Fan G, Li P, Yang E, Jing S, Shi Y, Gong Y, Zhang L, Wang Z. Chen C, et al. Clin Transl Oncol. 2024 Sep 12. doi: 10.1007/s12094-024-03694-z. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39266874 Review. - Exploring treatment options in cancer: Tumor treatment strategies.
Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Liu B, et al. Signal Transduct Target Ther. 2024 Jul 17;9(1):175. doi: 10.1038/s41392-024-01856-7. Signal Transduct Target Ther. 2024. PMID: 39013849 Free PMC article. Review. - Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.
ELfieky MMM, Abd El Rahman M, Fayed AM, Haleem Al-Qaim Z, Khalid Aldhalmi A, Ae Badr E, Abdel Aziz A, Ibrahim GMA. ELfieky MMM, et al. Asian Pac J Cancer Prev. 2024 Jun 1;25(6):2113-2121. doi: 10.31557/APJCP.2024.25.6.2113. Asian Pac J Cancer Prev. 2024. PMID: 38918674 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical